Aurinia Pharmaceuticals Celebrates New Lupus Nephritis Guidelines

Aurinia Pharmaceuticals (AUPH) has released an update.

Aurinia Pharmaceuticals applauds the American College of Rheumatology’s 2024 guidelines for lupus nephritis treatment, which recommend using their FDA-approved drug LUPKYNIS as part of a triple immunosuppressive therapy. The guidelines emphasize reducing steroid use and achieving specific proteinuria targets, highlighting the drug’s effectiveness demonstrated in clinical trials.

For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.